This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bae, S. H. Articles by Sin, J.-I. Search for Related Content PubMed PubMed Citation Articles by Bae, S. H. Articles by Sin, J.-I.

Therapeutic Synergy of Human Papillomavirus E7 Subunit Vaccines plus Cisplatin in an Animal Tumor Model: Causal Involvement of Increased Sensitivity of Cisplatin-Treated Tumors to CTL-Mediated Killing in Therapeutic Synergy

Authors' Affiliations: Departments of ¹ Hematology-Oncology, ² Microbiology, ³ Pathology, and ⁴ Obstetrics and Gynecology, Catholic University of Daegu, Daegu, Korea and ⁵ Department of Obstetrics and Gynecology, Flushing Hospital Medical Center, Flushing, New York

Requests for reprints: Jeong-Im Sin, Department of Microbiology, School of Medicine, Catholic University of Daegu, 3056-6, Daemyung-4-Dong, Namgu, Daegu, 705-718, Korea. Phone: 82-53-650-4338; Fax: 82-53-651-8327; E-mail: jsin1964{at}hanmail.net.

Purpose: The goal of this study was to investigate the therapeutic potentials of combining chemotherapy with human papillomavirus (HPV) E7 subunit vaccines in an animal tumor model and to determine the underlying therapeutic mechanisms.

Experimental Design: Animals bearing HPV E6/E7–expressing tumors were treated intratumorally with a selected cytotoxic drug, cisplatin, twice at 1-week interval and s.c. with E7 subunit vaccines thrice at 1-week interval. Tumor chemoimmunoresponse was measured by tumor size. Ag-specific CTL activities and tumor histology were checked in mice under treatments. Apoptosis, in vivo T-cell subset depletion, adoptive CTL transfer, and tumor regression were used to determine the mechanisms for antitumor therapeutic effects.

Results: Combined therapy using cisplatin plus E7 subunit vaccines improved cure and recurrence rates of tumors and long-term antitumor immunity dramatically more than single therapy alone. In particular, both components of E7 subunit vaccines were required for induction of Ag-specific CTL as well as therapeutic synergy when combined with cisplatin. This therapeutic synergy was abrogated by depletion of CD8⁺ T cells in vivo and was concomitant with histologic changes (such as heavy infiltration of lymphocytes and reduced tumor cell density). Finally, the increased sensitivity of cisplatin-treated tumors to CTL-mediated killing was found to be responsible for therapeutic synergy.

Conclusions: E7 subunit vaccines plus cisplatin mediate antitumor therapeutic synergy through the increased sensitivity of cisplatin-treated tumors to CTL-mediated killing. Moreover, E7-based therapeutic vaccines have the potential to improve chemotherapy in patients with cervical cancer.

This article has been cited by other articles:

				X. Huang, L. Zhuang, Y. Cao, Q. Gao, Z. Han, D. Tang, H. Xing, W. Wang, Y. Lu, G. Xu, et al. Biodistribution and kinetics of the novel selective oncolytic adenovirus M1 after systemic administration Mol. Cancer Ther., June 1, 2008; 7(6): 1624 - 1632. [Abstract] [Full Text] [PDF]

				C.-W. Tseng, C.-F. Hung, R. D. Alvarez, C. Trimble, W. K. Huh, D. Kim, C.-M. Chuang, C.-T. Lin, Y.-C. Tsai, L. He, et al. Pretreatment with Cisplatin Enhances E7-Specific CD8+ T-Cell-Mediated Antitumor Immunity Induced by DNA Vaccination Clin. Cancer Res., May 15, 2008; 14(10): 3185 - 3192. [Abstract] [Full Text] [PDF]